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Summary
Extra-label drug use (ELDU) is needed
to provide optimal therapy for ill dairy cattle.
Proper ELDU requires cooperat ion and
compliance between the veterinarian and
producer to ensure that proper drug with-
drawal times are observed. 
(Key Words: Regulations, Mastitis, Ther-
apy.)
A Severe Case of Clinical Mastitis
This case is presented as a “real-life”
situation in which the suitability and legality
of therapy will follow.  On August 21, a 6-
year-old 1400 lb Holstein cow 109 days in
milk is presented with a temperature of
101.8°F, a heart rate of 92, a respiratory rate
of 32, adequate rumen contractions, and a
noticeably swollen but not hard quarter.  She
is 7-9% dehydrated, depressed, not eating,
and not ketotic.  Upon exam of her milk
from the affected quarter, there are many
clots in the watery secretion.  There are no
other abnormalities present.  The first  step in
managing this cow would be to assess her
severity level, which could easily be severe
based on her elevated heart rate and her
dehydrat ion.  The next step would be to
approach the management of this case with
FANO (Fluids, Antibiotics, Non-steroidal
anti-inflammatory, and Other).  The cow is
7-9% dehydrated but still standing and the
rumen contractions seem normal.  Adminis-
ter 2 liters of 7% hypertonic saline followed
by at least 12 gallons of oral fluids spiked
with regular salt and diet salt. Because
around 30% of cows with severe mastitis
develop bacteria in the bloodstream, use a
good broad-spectrum antibiotic (Naxcel®).
Then collect a milk sample for culture and
treat intramammary (IMM) based on the
results of the culture the following day.
Administer 15 ml of an anti-inflammatory
drug (Banamine®) intramuscularly (i.m.)
and oral and subcutaneous calcium.
The following day E. coli grows as a
lawn (colonies too numerous to count) on
blood agar.   The cow is re-evaluated the
following morning and her temperature is
now 104, pulse 94, respiratory rate 38, her
rumen motility is still okay and she does not
appear dehydrated.  Continue the Naxcel at
the labeled dose and repeat the Banamine.
Treat her intramammary infusion with 6 ml
of ceftiofur HCl (Excenel®) twice daily for
3 days. Fluids were repeated on days 3 and 4.
Banamine was repeated on day 3.  Intramus-
cular Naxcel was continued through day 5.
Was My Clinical Mastitis
Therapy Legal?
Neither Naxcel nor Excenel have a label
claim for treatment of clinical mastitis.  Is
there any antibiotic approved for clinical
mastitis or bacteria in the blood for treatment
in lactating dairy cows?  No, but how would
you find this information?
• Go to the website:                                  
http://www.fda.gov/cvm/
• Click on “Greenbook”
• Click on “FDA Approved Animal Drug
Products On-Line Database System”
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• Click on “Approved Animal Drug Prod-
ucts (Advanced)”
• Type in the generic name of an
antimicrobial and refine the search by
adding a descriptor (e.g., amoxicillin and
cattle).  You could also enter mastitis.
• For this example:
Field Search Term Records
All Fields amoxicillin and cattle  4
• Now click on display records.
The only systemic use antibiotics with
label indications for lactating dairy cattle are
amoxicillin, ampicillin, ceftiofur, erythro-
mycin, oxytetracycline, penicillin, and
sulfadimethoxine.  None have label indica-
tions for clinical mastitis or bacteremia.
Therefore, systemic antimicrobial therapy for
treatment of clinical mastitis or bacteremia is
extralabel.  Was it an acceptable ELDU?
Extralabel Drug Use (ELDU)
• ELDU is not permitted if a drug exists
that is labeled for the food animal species
and contains the needed ingredient, in the
proper dosage form, labeled for the indi-
cation, and is clinically effective.  Okay
here.
• ELDU is permitted only by or under the
supervision of a veterinarian.  Okay here.
• ELDU is allowed only for FDA approved
animal and human drugs.  Okay here.
• ELDU is permitted for therapeutic pur-
poses only when an animal’s health is
suffering or threatened.  Okay here.
• ELDU is not permitted if it results in a
violative food residue, or any residue that
may present  a risk to public health.
Okay here.
• ELDU requires scientifically based drug
withdrawal times to ensure food safety.
Okay here.
An American Veterinary Medical Asso-
ciation (AVMA) ELDU algorithm has been
developed to help with these decisions:
http://www.avma.org/scienact/amduca/
amduca1.asp
One has a diagnosis of severe clinical
mastitis made in the presence of a valid
veterinary/client/patient relationship. When
contemplating extra-label drug use for sys-
temic antimicrobial therapy, one must ask:
1. Are the animals to be treated lactating
dairy cows (food animals)?  Yes or No. 
Yes, this is a food animal.
2. Does a lactating dairy cow (food animal)
labeled drug exist that fulfills all of the
following?  Yes or No.
C contains the needed ingredient
C in the proper dosage form
C labeled for the indication
C clinically effective
No, a labeled drug does not exist.
3. Is there a lactating dairy cow (food ani-
mal) approved drug which could be used
extra-label?  Yes or No.
Yes, an approved drug can be used
extra-label.
C Proceed with Extra-label use of food
animal drug. 
C Establish extended withdrawal time. 
C Ensure food safety.
C Maintain required records.
C Label drug appropriately.
Extralabel antimicrobial therapy must be
prescribed only in accordance with the Ani-
mal Medicinal Drug Use Clarification Act
amendments to the Food, Drug, and Cos-
metic Act and its regulations (21 CFR Part
530).  No drug can be marketed unless its
quality, safety, and efficacy have been dem-
onstrated.  Thus, the first  choice should be
based on the products approved for the spe-
cies and the indication concerned.  When no
suitable product is approved for a specific
condition or species, or the approved product
is considered to be clinically ineffective, the
choice of an alternative product should be
based, when possible, on the results of valid
scientific studies and a proven efficacy for
the condition and species concerned
(www.fda.gov/cvm/index/fdavet/2000/sept
vet.htm).  Based on ELDU guidelines and
the algorithm, antimicrobials not labeled for
lactating dairy cattle but still legal for use in
cattle would be okay to use.  However, it
would seem prudent to use products that are
approved for lactating dairy cattle as the
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meat and milk withdrawal times have been
scientifically validated.
When no approved drug is available or
when higher-than-approved dosages of
approved drugs are needed, veterinarians
must use their professional judgment regard-
ing the benefits and risks to sick animals
associated with extra-label use of drugs.
Extra-label use for analgesic purposes is
common because few animal-specific drugs
have been approved for the relief of pain and
suffering.  Was use of Banamine extralabel
and if so was its use appropriate?  The an-
swers to this are yes and yes.  Anti-inflam-
matory drugs are often used to treat cases of
clinical mastitis and none have a label claim
specific for mastitis.  However, our purpose
in administering these drugs is to decrease
fever, swelling, inflammation, and combat
endotoxin.  Based on reasons and listed
indications in Table 1, Banamine is an ac-
ceptable ELDU. 
In the U.S., the only intramammary
antibiotic labeled for clinical mastitis is
pirlimycin, which that  has proven efficacy
against staphylococcus and streptococcus
species.  Indications for some of the other
intramammary antibiotics imply clinical
mastitis therapy but use words such as acute
or chronic mastitis or administer at first  signs
of inflammation or any alterat ion in the milk.
So was the use of intramammary ceftiofur
HCL extralabel? Yes. But the use of intra-
mammary ceftiofur HCl appears to be an
appropriate ELDU because no approved and
proven effective products for severe clinical
coliform mastitis exist.  But  let’s go a step
further.  Are there other requirements? 
One of the provisions the AVMA per-
suaded the Center for Veterinary Medicine
(CVM) of the U.S. Food and Drug Adminis-
tration (FDA) to include in its regulations
allows extralabel use when an approved drug
is judged to be clinically ineffective for its
intended use.  But what about ampicillin
(Hetacin K) that has the only approved
intramammary label claim against E. coli.  I
could not find a single study published in a
peer-reviewed journal that reported on the
efficacy of intramammary ampicillin (as the
sole treatment) for clinical mastitis.
Ampicillin in combination with other antibi-
otics has been reported to be inferior to other
intramammary preparations.  However, when
the ampicillin and cloxacillin preparation
was compared only to itself with no controls,
the results looked a lot better.  When the
same ampicillin/cloxacillin preparation was
compared to either parenteral cefquinome
therapy, with or without intramammary
cefquinome (cures of 82.6 to 95.2%), against
experimentally induced E. coli, results indi-
cated that the ampicillin product (cures of
54.5%) was significantly inferior.  This study
supports the lack of efficacy of ampicillin
and cloxacillin in the treatment of clinical
coliform mastitis in dairy cows.
So what criteria must a practitioner use to
justify extralabel use in a situation where the
[approved] drug is ineffective?  There is
nothing in the regulations to guide veterinari-
ans in making this assessment.  FDA recog-
nizes that it is the professional judgment of a
veterinarian to make that  determination.
Veterinarians aren’t required to state their
criteria as to why they thought the drug was
ineffective but economics should not be used
as justification of ELDU.  So is the
extralabel intramammary use of ceftiofur
effective for severe clinical E. coli mastitis?
Yes, it is.  Figure 1 indicates the daily colony
forming units  (cfu) for the case presented.
The first two data points were prior to any
intramammary ceftiofur.  The third data
point was after the first treatment and al-
though it appears there was no effect on the
cfu, cfu decreased.  The cow was treated
once on day 2, twice on day 3, twice on day
4 and once more on day 5.  Only the case
cow is presented here but  this figure repre-
sents a typical cfu response of cows with
coliform mastitis treated with intramammary
ceftiofur.
Table 1. Anti-Inflammatory Drugs*
Approved Milk Meat
Drug Lactating Indication Withdraw Withdraw
Aspirin No official Fever reduction l d  1 d
FDA approval suggested suggested
Dexamethasone Yes Ketosis, inflammation 0 0
Predef 2X Yes Ketosis, inflammation 0 7 d
Flunixin No Pyrexia, endotoxemia, 4 d 4 d
  meglumine inflammation
Phenylbutazone No Inflammation of the   5d    45? d
musculoskeleton
Dipyrone No Prohibited
Ketoprofen No Inflammation and pain of the 1 d 7d
musculoskeleton
*A selected reference for extralabel use of nonsteroidal anti-inflammatory drugs can be
found in JAVMA 1997 Vol. 211, No. 7, pgs 860-861.
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Figure 1.Colony-Forming Units and Somatic Cell Count by Days Post-Mastitis for a
Case of Severe Clinical E. coli Mastitis.
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